In Vitro Immunogenicity Assessment of AAV Gene Therapy Vectors

Time: 2:00 pm
day: Day 2 Track 1 PM

Details:

  • Selecting less inflammatory AAV vector candidates
  • Identifying immunogenic epitopes in AAV capsids
  • Setting up the tools for immunosafety assessment

Speakers: